These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 10500759)

  • 1. Histopathologic findings in routine biopsies of renal transplant allografts.
    Toki K; Kyo M; Takahara S; Hatori M; Morozumi K; Ichimaru N; Wang JD; Ding XQ; Miyamoto M; Oka K; Kyakuno M; Kojima Y; Kokado Y; Okuyama A
    Transplant Proc; 1999 Sep; 31(6):2655-8. PubMed ID: 10500759
    [No Abstract]   [Full Text] [Related]  

  • 2. A comparative study of morphological characteristics of renal injuries of tacrolimus (FK506) and cyclosporin (CyA) in renal allografts: are the morphologic characteristics of FK506 and CyA nephrotoxicity similar?
    Morozumi K; Sugito K; Oda A; Takeuchi O; Fukuda M; Usami T; Oikawa T; Fujinami T; Koyama K; Takeda A; Yoshida A; Haba T; Tominaga Y; Uchida K; Yokoyama I; Takagi H
    Transplant Proc; 1996 Apr; 28(2):1076-8. PubMed ID: 8623232
    [No Abstract]   [Full Text] [Related]  

  • 3. Protocol biopsies in stable renal transplant patients under triple immunosuppression: results at 6 months.
    Rush DN; Jeffery JR; Gough J
    Transplant Proc; 1994 Oct; 26(5):2576. PubMed ID: 7940797
    [No Abstract]   [Full Text] [Related]  

  • 4. Risk factors of acute tacrolimus nephrotoxicity in renal allografts.
    Shimizu T; Tanabe K; Tokumoto T; Ishikawa N; Shimmura H; Oshima T; Toma H; Yamaguchi Y
    Transplant Proc; 2000 Nov; 32(7):1914-6. PubMed ID: 11119998
    [No Abstract]   [Full Text] [Related]  

  • 5. A comparative study of clinicopathologic characteristics of renal allografts under cyclosporine and FK506 immunosuppression.
    Sugito K; Morozumi K; Oikawa T
    Transplant Proc; 1996 Jun; 28(3):1335-7. PubMed ID: 8658683
    [No Abstract]   [Full Text] [Related]  

  • 6. Improvement of nephrotoxicity, hypertension, and lipid metabolism after conversion of kidney transplant recipients from cyclosporine to tacrolimus.
    Friemann S; Feuring E; Padberg W; Ernst W
    Transplant Proc; 1998 Jun; 30(4):1240-2. PubMed ID: 9636504
    [No Abstract]   [Full Text] [Related]  

  • 7. Conversion from cyclosporine to tacrolimus in kidney, kidney/pancreas, and pancreas alone transplant recipients: the Memphis experience.
    Alloway RR; Russell WC; Gaber LW; Amiri MH; Vera SR; Gaber AO
    Transplant Proc; 1996 Apr; 28(2):995-7. PubMed ID: 8623494
    [No Abstract]   [Full Text] [Related]  

  • 8. Calcineurin inhibitor toxicity in renal allografts: morphologic clues from protocol biopsies.
    Sharma A; Jain S; Gupta R; Guleria S; Agarwal S; Dinda A
    Indian J Pathol Microbiol; 2010; 53(4):651-7. PubMed ID: 21045386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conversion from cyclosporine to tacrolimus prevents transplant function loss due to acute steroid-resistant or chronic rejection in renal allograft recipients.
    Blume C; Hollenbeck M; Ivens K; Heering P; Hetzel GR; Grabensee B
    Transplant Proc; 2001; 33(7-8):3161-3. PubMed ID: 11750357
    [No Abstract]   [Full Text] [Related]  

  • 10. Histopathologic findings of renal allografts surviving more than 10 years after transplantation.
    Yamaguchi Y; Tanabe K; Shimizu T; Matsugami K; Fuchinoue S; Toma H; Agishi T
    Transplant Proc; 2000 Mar; 32(2):308-10. PubMed ID: 10715426
    [No Abstract]   [Full Text] [Related]  

  • 11. Conversion from tacrolimus to Neoral in liver and kidney transplant recipients.
    Ott R; Bussenius-Kammerer M; Scholz D; Neuhaus R; Tolba RH; Fricke L; Müller V
    Transplant Proc; 2001; 33(7-8):3166-8. PubMed ID: 11750359
    [No Abstract]   [Full Text] [Related]  

  • 12. Methods and outcomes of calcineurin inhibitor reduction or withdrawal in patients with chronic allograft nephropathy after the first year posttransplantation.
    Weir MR
    Transplant Proc; 2001 Jun; 33(4 Suppl):19S-28S. PubMed ID: 11406264
    [No Abstract]   [Full Text] [Related]  

  • 13. Correlation of clinical outcomes after tacrolimus conversion for resistant kidney rejection or cyclosporine toxicity with pathologic staging by the Banff criteria.
    Morrissey PE; Gohh R; Shaffer D; Crosson A; Madras PN; Sahyoun AI; Monaco AP
    Transplantation; 1997 Mar; 63(6):845-8. PubMed ID: 9089224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histopathologic findings from 2-year protocol biopsies from a U.S. multicenter kidney transplant trial comparing tarolimus versus cyclosporine: a report of the FK506 Kidney Transplant Study Group.
    Solez K; Vincenti F; Filo RS
    Transplantation; 1998 Dec; 66(12):1736-40. PubMed ID: 9884269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preliminary experience with FK 506 in pediatric renal transplant recipients: a single-center report.
    Birk PE; Cook ME; Schmidt WJ; Chavers BM
    Transplant Proc; 1996 Apr; 28(2):993-4. PubMed ID: 8623493
    [No Abstract]   [Full Text] [Related]  

  • 16. Tacrolimus (FK 506) in kidney transplantation.
    Vanrenterghem Y
    Transplant Proc; 1998 Aug; 30(5):2171-3. PubMed ID: 9723431
    [No Abstract]   [Full Text] [Related]  

  • 17. Preliminary analysis of a randomized trial comparing microemulsion cyclosporine and tacrolimus for recipients of renal transplants from non-heart-beating donors.
    Williams ST; Knight AL; White SA; Doughman TM; Nicholson ML
    Transplant Proc; 2000 Feb; 32(1):196. PubMed ID: 10701022
    [No Abstract]   [Full Text] [Related]  

  • 18. Use of mycophenolate mofetil in patients with chronic cyclosporine nephrotoxicity.
    Wombolt DG; McCune TR; Stewart M
    Transplant Proc; 1998 Jun; 30(4):1194. PubMed ID: 9636483
    [No Abstract]   [Full Text] [Related]  

  • 19. Role of protocol biopsies in the treatment of refractory renal allograft rejection with FK 506.
    Woodle ES; Thistlethwaite JR; Haas M; Josephson MA; Newell KA; Bruce DS; Millis JM; Piper JB; Charette JI
    Transplant Proc; 1996 Apr; 28(2):998-9. PubMed ID: 8623495
    [No Abstract]   [Full Text] [Related]  

  • 20. Conversion from Neoral (cyclosporine) to tacrolimus of kidney transplant recipients for gingival hyperplasia or hypertrichosis.
    Busque S; Demers P; St-Louis G; Boily JG; Tousignant J; Lemieux F; Smeesters C; Corman J; Daloze P
    Transplant Proc; 1998 Jun; 30(4):1247-8. PubMed ID: 9636507
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.